At Rapafusyn, our mission is to harness the power of non-degrading molecular glues to develop transformative therapies for patients with limited or no treatment options. Our proprietary platform expands the frontier of drug discovery by enabling selective targeting of challenging hard to drug intracellular proteins, offering new hope where conventional approaches fall short.

Our lead program targets the prevention of Acute Kidney Injury (AKI), a life-threatening complication of cardiac surgery with no approved therapies. In partnership with leading nephrologists at Johns Hopkins University, we are committed to advancing precision medicines that directly address the needs of underserved patient populations.

Rapafusyn was founded by Professor Jun O. Liu, a leading expert in the field of molecular glues. Dr. Liu’s pioneering research uncovered the mechanisms of FK506 and cyclosporine, and he later developed technology to extend the FKBP12-based mechanism to a broader range of disease-relevant targets. This breakthrough laid the foundation for Rapafusyn’s platform and mission.

*J Liu et al. Cell. 1991 Aug 23; 66(4):807-15

By using principles of rationale design and molecular diversity, the target classes that can be modulated by molecular glues has been greatly expanded beyond the historical targets of mTOR (Rapamycin) and calcineurin (FK506). Targets classes that now can be modulated by RapaGlues include PPIs, transcription factors, SLCs, enzymes, ligases, and kinases.